Artwork
iconShare
 
Manage episode 516147033 series 2740117
Content provided by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

💡 TARGET-FIRST trial (NEJM, Aug 2025) shows that in low-risk AMI patients post-PCI with complete revascularization, stopping aspirin after 1 month and continuing P2Y12 monotherapy is noninferior to dual antiplatelet therapy—with 54% fewer bleeding events 🩸🛑💊

⚖️ A modern, patient-tailored antiplatelet strategy—backed by potent P2Y12 inhibitors and smart selection—might just be the new norm in contemporary cardiology 🫀

📘 New England Journal of Medicine

🔗 https://doi.org/10.1056/NEJMoa2508808

#Cardiology #DAPT #PrecisionMedicine #NEJM #TARGETFIRST

  continue reading

772 episodes